Literature DB >> 10646869

Source of oncofetal ED-B-containing fibronectin: implications of production by both tumor and endothelial cells.

M Midulla1, R Verma, M Pignatelli, M A Ritter, N S Courtenay-Luck, A J George.   

Abstract

ED-B fibronectin (FN) is a FN isoform derived from alternative splicing of the primary transcript of a single gene. Its expression on tumor stroma and neoformed tumor vasculature and its absence, with few exceptions, in normal adult tissues imply a prognostic and diagnostic value for ED-B FN. We investigated the location and source of ED-B FN because this will be of importance both in understanding its role in tumor development and in designing strategies to target this molecule. We have confirmed that ED-B FN is expressed in the majority of breast and colorectal carcinoma tissue samples, with strong immunohistochemical staining around the tumor cells and in the tumor stroma. No staining of tumor neovasculature was seen. ED-B FN is produced by a range of tumor and endothelial (both primary and transformed) cell lines, as detected by reverse transcription-PCR, but is not expressed at the plasma membrane. Strong expression of human ED-B FN is seen in tumor xenografts. These data indicate that neoplastic cells can act as the source of ED-B FN in tumors. The lack of cell surface expression on tumor cell lines has clear implications for the design of therapeutic strategies which target this molecule.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10646869

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

Review 1.  Antibody-cytokine fusion proteins: applications in cancer therapy.

Authors:  Elizabeth Ortiz-Sánchez; Gustavo Helguera; Tracy R Daniels; Manuel L Penichet
Journal:  Expert Opin Biol Ther       Date:  2008-05       Impact factor: 4.388

2.  A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma.

Authors:  Sarah M Rudman; Michael B Jameson; Mark J McKeage; Philip Savage; Duncan I Jodrell; Mark Harries; Gary Acton; Fredrik Erlandsson; James F Spicer
Journal:  Clin Cancer Res       Date:  2011-03-29       Impact factor: 12.531

Review 3.  Progress in tumor vascular normalization for anticancer therapy: challenges and perspectives.

Authors:  Bingxue Shang; Zhifei Cao; Quansheng Zhou
Journal:  Front Med       Date:  2012-03-31       Impact factor: 4.592

Review 4.  Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment.

Authors:  Alain E Andrea; Andrada Chiron; Sarah Mallah; Stéphanie Bessoles; Guillaume Sarrabayrouse; Salima Hacein-Bey-Abina
Journal:  Front Immunol       Date:  2022-02-08       Impact factor: 7.561

5.  Epigenetic reversion of breast carcinoma phenotype is accompanied by changes in DNA sequestration as measured by AluI restriction enzyme.

Authors:  Tone Sandal; Klara Valyi-Nagy; Virginia A Spencer; Robert Folberg; Mina J Bissell; Andrew J Maniotis
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

Review 6.  New radiotracers for imaging of vascular targets in angiogenesis-related diseases.

Authors:  Hao Hong; Feng Chen; Yin Zhang; Weibo Cai
Journal:  Adv Drug Deliv Rev       Date:  2014-07-30       Impact factor: 15.470

7.  Integrin-mediated cell-matrix interaction in physiological and pathological blood vessel formation.

Authors:  Stephan Niland; Johannes A Eble
Journal:  J Oncol       Date:  2011-09-18       Impact factor: 4.375

8.  Antitumor Effects of CAR T Cells Redirected to the EDB Splice Variant of Fibronectin.

Authors:  Jessica Wagner; Elizabeth Wickman; Timothy I Shaw; Alejandro Allo Anido; Deanna Langfitt; Jinghui Zhang; Shaina N Porter; Shondra M Pruett-Miller; Heather Tillman; Giedre Krenciute; Stephen Gottschalk
Journal:  Cancer Immunol Res       Date:  2020-12-22       Impact factor: 12.020

Review 9.  Phenotypic and genetic alterations in mammary stroma: implications for tumour progression.

Authors:  S L Schor; A M Schor
Journal:  Breast Cancer Res       Date:  2001-09-06       Impact factor: 6.466

Review 10.  Migratory neighbors and distant invaders: tumor-associated niche cells.

Authors:  Jared Wels; Rosandra N Kaplan; Shahin Rafii; David Lyden
Journal:  Genes Dev       Date:  2008-03-01       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.